Zai Lab announced China 's NMPA has approved Qinlock® (ripretinib) to launch as a treatment for advanced gastrointestinal stromal tumors (GIST). The indication is for adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib. In 2019, Zai acquired China rights to Qinlock, which targets a broad spectrum of KIT and PDGFRα mutations known to drive GIST, from Deciphera in a $205 million deal. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) (NSDQ: DCPH) Share this with colleagues: // //